Osteosarcoma Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape, 2021-2027
Summary
This reports provides a data-driven overview of the current and future competitive landscape in osteosarcoma therapeutics.
In osteosarcoma Cells expressing ganglioside GD2 is a major focus of drug developers. There are 131 drugs in the pipeline with 98% molecules present in early-to-mid stage. Mid-sized Pharma dominates clinical development in this space. More frequent use of newer symptomatic treatments are expected to drive the market. However, the market growth is limited by higher usage of generic medicines, and due to high cost associated with osteosarcoma therapies.
Scope
GlobalData’s Osteosarcoma Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape, 2021-2027 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook